CHIKUNGUNYA VIRUS INFECTION
Clinical trials for CHIKUNGUNYA VIRUS INFECTION explained in plain language.
Never miss a new study
Get alerted when new CHIKUNGUNYA VIRUS INFECTION trials appear
Sign up with your email to follow new studies for CHIKUNGUNYA VIRUS INFECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New chikungunya vaccine enters first human tests
⭐️ VACCINE ⭐️ Not yet recruitingThis early-phase trial tests a new vaccine called PepGNP-ChikV, designed to protect against chikungunya virus. About 40 healthy adults aged 18 to 60 will receive two shots, 42 days apart, and be monitored for safety and immune response for a year. The vaccine uses tiny nanopartic…
Matched conditions: CHIKUNGUNYA VIRUS INFECTION
Phase: EARLY_PHASE1 • Sponsor: Gylden Pharma Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 13:01 UTC
-
Chikungunya vaccine safety in pregnancy under review
Knowledge-focused Not yet recruitingThis study looks at the safety of a chikungunya vaccine (VLA1553) given to pregnant women in Brazil. Researchers will track pregnancy and baby health outcomes for up to 12 weeks after birth in 200 vaccinated women and compare them to a similar group of pregnant women who received…
Matched conditions: CHIKUNGUNYA VIRUS INFECTION
Sponsor: Valneva Austria GmbH • Aim: Knowledge-focused
Last updated May 17, 2026 12:55 UTC